Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06788171 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Dec 1, 2026 → Sep 1, 2027
See other at-risk trials from Fujian Cancer Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 1, 2026 to Sep 1, 2027 Show 4 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 1, 2025 to May 9, 2026
    • Eligibility criteria expanded, about 113 words
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Trial Details
NCT Number NCT06788171
Lead Sponsor Fujian Cancer Hospital
Conditions
(from sponsor)		 Colorectal Cancer Liver Metastasis
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov